Expanded access policy

Graphite Bio is committed to developing safe and effective novel therapies to treat hemoglobinopathies and other serious diseases.

Due to the complex nature of gene therapy treatment and our current phase of clinical development, we currently provide access to our investigational therapies only through a clinical trial.

Patients are encouraged to participate in clinical trials of our investigational therapies whenever possible. Our clinical trials are designed, conducted, and monitored to ensure that the safety and efficacy of our investigational therapies are further evaluated. These studies will be submitted to regulatory agencies for review with the intent to make them more broadly available to patients.

Additional information about our clinical trials is available to you and your physician on our website www.lenztxstg.wpenginepowered.com, or the NIH website www.clinicaltrials.gov by searching for “Graphite Bio.”

If you are a healthcare professional and have questions about participating in one of our clinical studies or about one of our investigational therapies, please email medinfo@graphitebio.com and our team will respond as soon as possible, usually within 5 business days of receipt.

In accordance with the 21st Century Cures Act, we may revise this policy at any time.